Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 19/20 | 1.00 |
| ▸ | CYSLTR1 | Q9Y271 | 19/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6965141 | 1.00 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1GPBAR1 | |
| SCHEMBL30383176 | 1.00 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1GPBAR1 | |
| SCHEMBL6177533 | 0.92 | CYSLTR1 (1.00) | CYSLTR2CYSLTR1 | |
| SCHEMBL6177529 | 0.92 | CYSLTR1 (1.00) | CYSLTR2CYSLTR1 | |
| SCHEMBL6965832 | 0.89 | CYSLTR1 (1.00) | CYSLTR2CYSLTR1GPBAR1 | |
| SCHEMBL6965825 | 0.89 | CYSLTR1 (1.00) | CYSLTR2CYSLTR1GPBAR1 | |
| SCHEMBL30382705 | 0.89 | CYSLTR1 (1.00) | CYSLTR2CYSLTR1GPBAR1 | |
| SCHEMBL8192801 | 0.88 | CYSLTR1 (0.78) | CYSLTR2CYSLTR1GPBAR1 | |
| SCHEMBL6969967 | 0.86 | CYSLTR1 (1.00) | CYSLTR2CYSLTR1 | |
| SCHEMBL6962892 | 0.86 | CYSLTR1 (1.00) | CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-0902007-B1 | CHALCONE DERIVATIVES AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2003-11-05 | — | — | EP | disclosed |
| EP-0902007-A1 | CHALCONE DERIVATIVES AND DRUGS CONTAINING THE SAME | KOWA CO. LTD. (JP) | 1999-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | CYSLTR2 3789/4885CYSLTR1 3956/4885GPBAR1 4425/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | CYSLTR2 2710/4885CYSLTR1 2263/4885GPBAR1 4291/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | CYSLTR2 2710/4885CYSLTR1 2263/4885GPBAR1 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.